Hyperglycemia and Cancer: An Algorithm to Guide Oncology Nurses

Sampayo, Veronica; Tofthagen, Cindy

doi:10.1188/17.cjon.345-352

Cited by 4 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many epidemiological reports have shown that diabetes is positively associated with several types of cancers including breast, colorectal, endometrial, liver and pancreatic cancers. On the other hand, a decreased prevalence of prostate cancer has been observed in diabetic patients [11]. Ben et al found a significant association between DM and pancreatic with an inverse correlation between the duration of DM and the occurrence of pancreatic cancer in both sexes, thus observing the greatest risk of developing pancreatic cancer in patients with a duration of DM shorter than 1 year after diagnosis [12].…”

Section: Introductionmentioning

confidence: 99%

Diabetes and Cancer: Metabolic Association, Therapeutic Challenges, and the Role of Natural Products

et al. 2021

View full text Add to dashboard Cite

Cancer is considered the second leading cause of death worldwide and in 2018 it was responsible for approximately 9.6 million deaths. Globally, about one in six deaths are caused by cancer. A strong correlation was found between diabetes mellitus and carcinogenesis with the most evident correlation was with type 2 diabetes mellitus (T2DM). Research has proven that elevated blood glucose levels take part in cell proliferation and cancer cell progression. However, limited studies were conducted to evaluate the efficiency of conventional therapies in diabetic cancer patients. In this review, the correlation between cancer and diabetes will be discussed and the mechanisms by which the two diseases interact with each other, as well as the therapeutics challenges in treating patients with diabetes and cancer with possible solutions to overcome these challenges. Natural products targeting both diseases were discussed with detailed mechanisms of action. This review will provide a solid base for researchers and physicians to test natural products as adjuvant alternative therapies to treat cancer in diabetic patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Diabetes and Cancer: Metabolic Association, Therapeutic Challenges, and the Role of Natural Products

et al. 2021

View full text Add to dashboard Cite

show abstract

Optimal hyperglycemia thresholds in patients undergoing chemotherapy: a cross sectional study of oncologists’ practices

Salgado,

Birari,

Alshahawey

et al. 2024

Support Care Cancer

View full text Add to dashboard Cite

Purpose Neither the United States nor the European oncology guidelines include details for appropriate management of hyperglycemia in cancer patients. The aim was to identify fasting and random blood glucose thresholds, and hemoglobin A1c (HbA1c) targets used by oncologists in clinical practice when managing hyperglycemia in patients with cancer undergoing chemotherapy. Methods This national, cross sectional study utilized a questionnaire to collect oncologists’ perceptions about optimal blood glucose thresholds and HbA1c targets in patients with cancer undergoing chemotherapy. Descriptive statistics were calculated to summarize glucose thresholds, HbA1c targets, and sample characteristics. Responses to an open-ended question about oncologists’ approach to hyperglycemia management were analyzed via thematic analysis using an inductive approach. Results Respondents (n = 229) were on average 52.1 years of age, 67.7% men, and 91.3% White. For patients without diabetes but experiencing hyperglycemia, oncologists targeted lower and upper fasting blood glucose levels between 75-121 mg/dL and 105-135 mg/dL, respectively. For patients with diabetes, the targets for lower and upper fasting blood glucose levels ranged between 100-130 mg/dL and 128-150 mg/dL, respectively. Fasting blood glucose (95.6%) and HbA1c (78.6%) were the most commonly used clinical indicators to consider chemotherapy dose reduction, delay, or discontinuation due to hyperglycemia in patients receiving chemotherapy with curative intent. Among those receiving palliative intent chemotherapy, the preferred clinical parameters were random blood glucose (90.0%), patient-reported blood glucose readings (70.7%), continuous glucose monitoring readings (65.1%), and patient-reported symptoms of hyperglycemia (65.1%). Three main themes emerged about oncologists’ approach to hyperglycemia management: 1) identification of high-risk patients; 2) need for early identification, screening, and diagnosis of hyperglycemia; and 3) multiple hyperglycemia management strategies. Conclusion Oncologists reported a wide variation of target blood glucose ranges considered appropriate in patients undergoing chemotherapy. Lack of clear guidance for hyperglycemia management during chemotherapy in the United States may be contributing to a lack of consistency in clinical practice.

show abstract

Steroid-induced diabetes in cancer patients

Dinn

2019

Journal of Prescribing Practice

View full text Add to dashboard Cite

Cancer and its treatments commonly require steroids to manage their side effects. Steroids increase blood glucose levels, causing new hyperglycaemia in patients with no known history of diabetes, termed steroid-induced diabetes mellitus (SIDM). This paper explores SIDM in cancer patients, identifying areas that could influence positive changes in current and future practice in its management and discuss their impact on practice in an outpatient setting. This paper concludes that active encouragement from staff can lead to an improved patient experience, as well as developing patient-led decisions and promoting self-managment

show abstract

Hyperglycemia and Cancer: An Algorithm to Guide Oncology Nurses

Abstract: All participants found the educational program effective and deemed the clinical algorithm useful. Results improved significantly after participation in the educational intervention.

Cited by 4 publications

References 25 publications

Diabetes and Cancer: Metabolic Association, Therapeutic Challenges, and the Role of Natural Products

Diabetes and Cancer: Metabolic Association, Therapeutic Challenges, and the Role of Natural Products

Optimal hyperglycemia thresholds in patients undergoing chemotherapy: a cross sectional study of oncologists’ practices

Steroid-induced diabetes in cancer patients

Contact Info

Product

Resources

About